# IRulya Therapeutics Inc. (IRLA)

Source: https://www.quantisnow.com/company/IRLA
Generated: 2026-11-13T11:10:41.206Z

- Ticker: IRLA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2019
- SEC CIK: 0001662774
- Website: https://www.quincetx.com

## About

Quince Therapeutics, Inc. is committed to transforming the lives of patients facing serious, underserved diseases by developing disease-modifying therapies to treat their conditions. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH). A Phase 2a study in PH patients has been completed, a Phase 2 clinical study in BOS patients is ongoing, a Phase 2b study in PH-ILD is ongoing, and a Phase 2 study in SAPH is anticipated to begin in late 2026. By pioneering innovative approaches, the company aims to offer new hope and improved quality of life to patients worldwide.

## Latest IRLA news and filings

- 2026-11-12 21:10 UTC [SEC Form 4] [Director Wise John Drayton was granted 17,000 director stock options (SEC Form 4)](https://www.quantisnow.com/insight/director-wise-john-drayton-was-granted-17000-director-stock-options-6787940)
- 2026-11-12 21:10 UTC [SEC Form 4] [Director Valentine James Elwood was granted 17,000 director stock options (SEC Form 4)](https://www.quantisnow.com/insight/director-valentine-james-elwood-was-granted-17000-director-stock-options-6787937)
- 2026-11-12 21:10 UTC [SEC Form 4] [Chief Financial Officer Militello John was granted 80,000 units of Common Stotck (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-militello-john-was-granted-80000-units-of-6787934)
- 2026-11-12 21:10 UTC [SEC Form 4] [Director Patterson Leone D was granted 17,000 director stock options (SEC Form 4)](https://www.quantisnow.com/insight/director-patterson-leone-d-was-granted-17000-director-stock-options-6787932)
- 2026-11-12 21:10 UTC [SEC Form 4] [Director Bonuccelli Catherine M. was granted 17,000 director stock options (SEC Form 4)](https://www.quantisnow.com/insight/director-bonuccelli-catherine-m-was-granted-17000-director-stock-options-6787931)
- 2026-11-09 21:01 UTC [IRulya Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/irulya-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6781040)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/IRLA
- Earnings history: https://www.quantisnow.com/earnings/IRLA
- Dividend history: https://www.quantisnow.com/dividends/IRLA
- Insider transactions: https://www.quantisnow.com/insiders/IRLA
- Options chain: https://www.quantisnow.com/options/IRLA
- SEC 8-K filings only: https://www.quantisnow.com/company/IRLA/8-k
- RSS and alerts for IRLA: https://www.quantisnow.com/docs/rss-feeds.md